Compare Campbell Soup Co. (CPB) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs 10X Genomics Inc — how do they compare? Campbell Soup Co. trades at $22.67 (market cap $6.78B), while 10X Genomics Inc trades at $58.04 (market cap $7.61B). The key difference: Campbell Soup Co. and 10X Genomics Inc are close in size by market cap, and Campbell Soup Co. pays a 6.87% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| CPB | TXG | |
|---|---|---|
Market Cap | $6.78B | $7.61B |
Sector | Consumer Staples | Health |
52-Week High | $34.03 | $58.57 |
52-Week Low | $20.00 | $11.34 |
Enterprise Value | $13.38B | $7.14B |
Dividend Yield | 6.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $22.42, down 2.73% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 EPS of $0.50, beating expectations of $0.4789, while Q4 2025 missed estimates. Revenue reached $10.25B in 2025 with a net income margin of 6.12%, though profitability metrics like ROE (3.09%) remain modest. Recent news highlights product innovation with new protein soups and leadership transitions aimed at business transformation.
The outlook for CPB is cautious with a consensus price target of $20.20 below the current price, reflecting analyst skepticism (58.62% Hold, 37.93% Sell). Opportunities include cost-saving initiatives and a sustainable ~7% dividend yield, but risks involve margin pressures, high debt levels, and competitive challenges in the packaged foods sector. Investors should weigh the dividend appeal against structural profitability concerns.
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
